Aarti Drugs Limited announced its audited standalone and consolidated financial results for Q3 FY26 and the nine months ending December 31, 2025. The board approved an interim dividend of ₹2 per equity share. Key management personnel changes were also approved, reflecting organizational alignment. The results highlight the company’s performance and strategic decisions for future growth.
Interim Dividend Declared
The Board of Directors has approved an interim dividend of ₹2 per equity share (20% of face value) for the financial year 2025-26. The record date for determining shareholders eligible for the dividend is February 9, 2026. Payout is ₹18,25,40,000.
Key Personnel Appointments
The company has included key functional heads in the list of “Senior Management Personnel”, effective February 3, 2026, to align with recent organizational changes:
- Shri Arun M. Patil, Vice President – Marketing
- Shri Digvir Jadeja, Vice President – Export Marketing
- Shri Jatin Chheda, Manager – Purchase
Q3 FY26 Financial Highlights (Standalone)
The Audited Standalone results for Q3 FY26 show:
- Revenue from operations: ₹52,880 lakhs
- Profit before tax: ₹2,171 lakhs
- Profit after tax: ₹3,384 lakhs
- Earnings per share: ₹3.71
Nine-Month Financial Highlights (Standalone)
The Audited Standalone results for the nine months ending December 31, 2025, show:
- Revenue from operations: ₹1,62,871 lakhs
- Profit before tax: ₹12,274 lakhs
- Profit after tax: ₹12,426 lakhs
- Earnings per share: ₹13.61
Q3 FY26 Financial Highlights (Consolidated)
The Audited Consolidated results for Q3 FY26 show:
- Revenue from operations: ₹60,171 lakhs
- Profit before tax: ₹2,902 lakhs
- Profit after tax: ₹4,054 lakhs
- Earnings per share: ₹4.44
Nine-Month Financial Highlights (Consolidated)
The Audited Consolidated results for the nine months ending December 31, 2025, show:
- Revenue from operations: ₹1,84,501 lakhs
- Profit before tax: ₹14,054 lakhs
- Profit after tax: ₹13,968 lakhs
- Earnings per share: ₹15.30
Additional Information
The company’s new manufacturing plant at Sayakha, Gujarat, commenced commercial production on September 4, 2025. The company completed a buyback of shares on September 24, 2024.
Source: BSE
